ASKA Pharmaceutical Holdings Co.,Ltd. (4886.T)
JPY 2041.0
(-0.34%)
JPY 2041.0
(-0.34%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 30.66 Billion JPY | 7.28% |
| 2022 | 28.58 Billion JPY | 8.47% |
| 2021 | 26.35 Billion JPY | 3.82% |
| 2020 | 25.38 Billion JPY | 5.69% |
| 2019 | 24.01 Billion JPY | 27.13% |
| 2018 | 18.89 Billion JPY | 0.03% |
| 2017 | 18.88 Billion JPY | -0.15% |
| 2016 | 18.91 Billion JPY | 10.32% |
| 2015 | 17.14 Billion JPY | -0.29% |
| 2014 | 17.19 Billion JPY | 0.72% |
| 2013 | 17.07 Billion JPY | -4.68% |
| 2012 | 17.9 Billion JPY | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 7.73 Billion JPY | -5.31% |
| 2024 Q1 | 8.17 Billion JPY | 16.16% |
| 2023 FY | 30.66 Billion JPY | 7.28% |
| 2023 Q1 | 7.46 Billion JPY | 20.02% |
| 2023 Q2 | 7.72 Billion JPY | 3.47% |
| 2023 Q3 | 8.44 Billion JPY | 9.34% |
| 2023 Q4 | 7.03 Billion JPY | -16.7% |
| 2022 Q4 | 6.21 Billion JPY | -22.88% |
| 2022 FY | 28.58 Billion JPY | 8.47% |
| 2022 Q3 | 8.06 Billion JPY | 14.38% |
| 2022 Q2 | 7.05 Billion JPY | -2.79% |
| 2022 Q1 | 7.25 Billion JPY | 28.17% |
| 2021 Q3 | 7.26 Billion JPY | 7.9% |
| 2021 FY | 26.35 Billion JPY | 3.82% |
| 2021 Q4 | 5.65 Billion JPY | -22.15% |
| 2021 Q2 | 6.73 Billion JPY | 0.69% |
| 2021 Q1 | 6.69 Billion JPY | 32.32% |
| 2020 Q3 | 7.48 Billion JPY | 10.66% |
| 2020 FY | 25.38 Billion JPY | 5.69% |
| 2020 Q1 | 6.07 Billion JPY | 11.39% |
| 2020 Q2 | 6.76 Billion JPY | 11.39% |
| 2020 Q4 | 5.05 Billion JPY | -32.47% |
| 2019 Q2 | 5.46 Billion JPY | -17.65% |
| 2019 Q3 | 6.47 Billion JPY | 18.57% |
| 2019 Q4 | 5.45 Billion JPY | -15.77% |
| 2019 Q1 | 6.63 Billion JPY | 69.7% |
| 2019 FY | 24.01 Billion JPY | 27.13% |
| 2018 FY | 18.89 Billion JPY | 0.03% |
| 2018 Q4 | 3.9 Billion JPY | -29.44% |
| 2018 Q3 | 5.53 Billion JPY | 33.68% |
| 2018 Q2 | 4.14 Billion JPY | -21.92% |
| 2018 Q1 | 5.3 Billion JPY | 50.58% |
| 2017 FY | 18.88 Billion JPY | -0.15% |
| 2017 Q2 | 4.76 Billion JPY | -5.98% |
| 2017 Q3 | 5.53 Billion JPY | 16.37% |
| 2017 Q4 | 3.52 Billion JPY | -36.4% |
| 2017 Q1 | 5.06 Billion JPY | 12.26% |
| 2016 FY | 18.91 Billion JPY | 10.32% |
| 2016 Q1 | 4.48 Billion JPY | 30.18% |
| 2016 Q2 | 4.8 Billion JPY | 7.27% |
| 2016 Q3 | 5.11 Billion JPY | 6.34% |
| 2016 Q4 | 4.51 Billion JPY | -11.79% |
| 2015 Q4 | 3.44 Billion JPY | -35.33% |
| 2015 Q3 | 5.32 Billion JPY | 31.59% |
| 2015 Q2 | 4.04 Billion JPY | -6.58% |
| 2015 Q1 | 4.33 Billion JPY | 10.54% |
| 2015 FY | 17.14 Billion JPY | -0.29% |
| 2014 Q3 | 4.46 Billion JPY | -0.45% |
| 2014 Q1 | 4.33 Billion JPY | 32.25% |
| 2014 FY | 17.19 Billion JPY | 0.72% |
| 2014 Q4 | 3.91 Billion JPY | -12.15% |
| 2014 Q2 | 4.48 Billion JPY | 3.34% |
| 2013 Q3 | 5.03 Billion JPY | 26.27% |
| 2013 Q1 | 4.77 Billion JPY | 12.22% |
| 2013 Q2 | 3.98 Billion JPY | -16.54% |
| 2013 FY | 17.07 Billion JPY | -4.68% |
| 2013 Q4 | 3.27 Billion JPY | -34.86% |
| 2012 FY | 17.9 Billion JPY | 0.0% |
| 2012 Q4 | 4.25 Billion JPY | -12.16% |
| 2012 Q2 | 4.23 Billion JPY | 0.0% |
| 2012 Q3 | 4.84 Billion JPY | 14.3% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 48.75 Billion JPY | 37.1% |
| Takeda Pharmaceutical Company Limited | 2184.96 Billion JPY | 98.597% |
| Sumitomo Pharma Co., Ltd. | 187.98 Billion JPY | 83.687% |
| Shionogi & Co., Ltd. | 369.08 Billion JPY | 91.692% |
| Wakamoto Pharmaceutical Co.,Ltd. | 3.54 Billion JPY | -766.035% |
| Nippon Shinyaku Co., Ltd. | 97.01 Billion JPY | 68.392% |
| Kaken Pharmaceutical Co., Ltd. | 38.22 Billion JPY | 19.771% |
| Eisai Co., Ltd. | 586.41 Billion JPY | 94.771% |
| Morishita Jintan Co., Ltd. | 5.99 Billion JPY | -411.254% |
| Hisamitsu Pharmaceutical Co., Inc. | 78.97 Billion JPY | 61.169% |
| Mochida Pharmaceutical Co., Ltd. | 52.07 Billion JPY | 41.108% |
| Fuso Pharmaceutical Industries,Ltd. | 13.51 Billion JPY | -126.862% |
| Nippon Chemiphar Co., Ltd. | 7.73 Billion JPY | -296.291% |
| Tsumura & Co. | 68.81 Billion JPY | 55.44% |
| Kissei Pharmaceutical Co., Ltd. | 37.34 Billion JPY | 17.878% |
| Torii Pharmaceutical Co., Ltd. | 24.79 Billion JPY | -23.689% |
| Towa Pharmaceutical Co., Ltd. | 81.38 Billion JPY | 62.32% |
| Fuji Pharma Co., Ltd. | 16.51 Billion JPY | -85.68% |
| Zeria Pharmaceutical Co., Ltd. | 50.18 Billion JPY | 38.892% |
| KYORIN Holdings, Inc. | 51.4 Billion JPY | 40.34% |
| Taiko Pharmaceutical Co.,Ltd. | 1.07 Billion JPY | -2741.983% |
| Daito Pharmaceutical Co.,Ltd. | 9.83 Billion JPY | -211.668% |
| SymBio Pharmaceuticals Limited | 4.41 Billion JPY | -595.192% |
| MedRx Co., Ltd | 26 Million JPY | -117842.308% |
| Mizuho Medy Co.,Ltd. | 8.02 Billion JPY | -282.084% |
| Solasia Pharma K.K. | 337 Million JPY | -8999.407% |
| Modalis Therapeutics Corporation | -731 Thousand JPY | 4195038.44% |
| Sawai Group Holdings Co., Ltd. | 54.31 Billion JPY | 43.546% |
| Cyfuse Biomedical K.K. | 37.74 Million JPY | -81144.701% |
| Toho Holdings Co., Ltd. | 112.98 Billion JPY | 72.859% |
| Koa Shoji Holdings Co.,Ltd. | 6.63 Billion JPY | -361.85% |